ANGOHealthcare · Medical Instruments & SuppliesThe 4 Wall Street analysts covering AngioDynamics, Inc. hold a median 12-month price target of $20 — +23.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 89 of 100 as at 13 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores AngioDynamics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (92): Reported profit is backed by cash, and the company is not expanding recklessly.
Issuance (33): The company has been issuing shares or taking on financing, diluting existing holders.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on ANGO, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +23.0% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 15 July 2026 | Canaccord Genuity | Maintains | Buy | $16 → $20 |
| 15 July 2026 | HC Wainwright & Co. | Maintains | Buy | $16 → $19 |
| 6 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 6 Apr 2026 | Canaccord Genuity | Maintains | Buy | $18 → $16 |
| 6 Apr 2026 | Freedom Broker | Initiates | Buy | — |
| 6 Apr 2026 | Freedom Broker | Initiates | Buy | $16 |
| 3 Oct 2025 | Canaccord Genuity | Maintains | Buy | — |
| 16 July 2025 | Canaccord Genuity | Maintains | Buy | — |
| 16 July 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 16 July 2025 | Lake Street | Initiates | Buy | — |
| 7 Apr 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 10 Jan 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Jan 2025 | Canaccord Genuity | Maintains | Buy | — |
| 10 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 Oct 2024 | Canaccord Genuity | Maintains | Buy | — |
| 4 Oct 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 20 Sept 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 17 July 2024 | Canaccord Genuity | Maintains | Buy | — |
| 17 July 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 22 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ANGO appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 19% of US stocks
Cheaper than 53% of US stocks
Cheaper than 28% of US stocks
Cheaper than 1% of US stocks
Higher than 47% of US stocks
Higher than 46% of US stocks
Higher than 67% of US stocks
Higher than 26% of US stocks
Higher than 19% of US stocks
Higher than 31% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own AngioDynamics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
AngioDynamics (ANGO) reported earnings 30 days ago, and its stock price has risen 8.9% since that report.
Why it matters — The article examines whether the stock can maintain its post-earnings momentum, which is relevant to investors tracking the company's near-term outlook.
AngioDynamics executives stated during a Canaccord fireside chat that the company expects its MedTech business to become the majority of company revenue in fiscal 2027. This reflects a multiyear shift away from slower-growth legacy markets toward higher-growth medical technology platforms.
Why it matters — A watcher would care because this signals that AngioDynamics is making progress in its strategic transition toward faster-growing medical technology segments, which could reshape the company's revenue composition.
Zacks notes AngioDynamics' Med Tech growth and reimbursement gains are bolstering its outlook, but tariffs, rising costs, and execution risks continue to cloud the investment case. The article weighs these supportive factors against ongoing margin pressure and uncertainty.
Why it matters — A watcher of ANGO would want to track how its growth and reimbursement momentum is being offset by margin headwinds, since this balance shapes the company's near-term financial outlook.
AngioDynamics' fiscal 2027 outlook centers on Med Tech growth offsetting flat device sales, while tariffs, spending, and losses are expected to pressure margins.
Why it matters — ANGO watchers would care because the FY27 guidance highlights both the growth driver (Med Tech) and the key risks (tariffs and margin pressure) shaping the company's near-term outlook.
AngioDynamics' stock jumped 33.5% over three months, a rally attributed to Med Tech growth. However, the article notes that valuation concerns, tariffs and negative earnings keep execution risks high, raising questions about whether the rally can continue.
Why it matters — ANGO watchers would care because the article questions whether the recent 33.5% rally is sustainable given the valuation, tariff and earnings risks that could weigh on the stock.
The 4 Wall Street analysts covering AngioDynamics, Inc. have a median 12-month price target of $20, with estimates ranging from $17 to $24. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 4 analysts covering AngioDynamics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks AngioDynamics, Inc. 89 out of 100 across roughly 4,600 US stocks as at 13 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 13 Aug 2026, AngioDynamics, Inc. ranks 89 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (92 of 100).
No one can know that. What the data says: the median 12-month target from 4 analysts implies +23.0% from the last close, and Ticker Nerd's factor model ranks AngioDynamics, Inc. 89 out of 100 as at 13 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering AngioDynamics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ANGO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $17 to $24 over the next 12 months.
AngioDynamics, Inc. returned +81.6% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
AngioDynamics Inc. is a medical technology company that designs, manufactures, and sells medical, surgical, and diagnostic devices for treating peripheral vascular disease, oncology, and surgical applications in the United States and internationally.
The most recent item we track (Zacks Investment Research, 13 Aug 2026): "AngioDynamics (ANGO) Up 8.9% Since Last Earnings Report: Can It Continue?". AngioDynamics (ANGO) reported earnings 30 days ago, and its stock price has risen 8.9% since that report.
AngioDynamics Inc. is a medical technology company that designs, manufactures, and sells medical, surgical, and diagnostic devices for treating peripheral vascular disease, oncology, and surgical applications in the United States and internationally. The company focuses on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life through innovative minimally invasive solutions. Key products include the Auryon Atherectomy system, which uses optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium, and the AlphaVac mechanical thrombectomy system for emergent aspiration in thrombus management. Its portfolio also encompasses ablation systems, fluid management systems, vascular access products, angiographic devices, drainage solutions, thrombolytics, and venous products. Operating through Med Tech and Med Device segments, AngioDynamics Inc. supports healthcare professionals worldwide with facilities in North America, Europe, APAC, the Middle East, and South America. Founded in 1988 and headquartered in Latham, New York, it remains a key player in the medical devices sector serving peripheral vascular and oncology needs.
CEO Mr. James C. Clemmer · 632 employees · United States · https://www.angiodynamics.com